Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.|Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
Keisuke
K
Imafuku
Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.
Koji
K
Yoshino
Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.
Kei
K
Yamaguchi
Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.
Satoshi
S
Tsuboi
Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.
Kuniaki
K
Ohara
Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
Hiroo
H
Hata
D060908:CTLA-4 Antigen; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma; D061026:Programmed Cell Death 1 Receptor; D012878:Skin Neoplasms
D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor